FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
January 23, 2006
Commission File Number 001-14978
SMITH & NEPHEW plc
(Registrant's name)
15 Adam Street
London, England WC2N 6LA
(Address of registrant's principal executive offices)
[Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.]
Form 20-F X Form 40-F
--- ---
[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1).]
Yes No X
--- ---
[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7).]
Yes No X
--- ---
[Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing information to the
Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of
1934.]
Yes No X
--- ---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b) : 82- n/a.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Smith & Nephew plc
(Registrant)
Date: January 23, 2006
By: /s/ Paul Chambers
-----------------
Paul Chambers
Company Secretary
Smith & Nephew Redenominates Share Capital
23 January 2006
Smith & Nephew plc (LSE: SN, NYSE: SNN) announces today that further to previous
announcements the share capital of the company has been redenominated into US
dollars by way of a reduction in capital and subsequent issue and allotment of
new dollar ordinary shares. The redenomination of the share capital was
approved by shareholders on 12 December 2005 and Court approval for the
reduction was received on 18 January 2006. The redenomination has been
registered at Companies House.
The nominal value of each dollar denominated ordinary share is now 20 cents.
Following this redenomination, shareholders receive one new dollar denominated
ordinary share for each sterling ordinary share held. The new shares have the
same rights and restrictions as the previously issued sterling ordinary shares.
The rights and obligations of the company's American Depositary Shares (ADS),
which are listed on the New York Stock Exchange, are not affected by the
redenomination and each ADS will continue to represent 5 ordinary shares.
Application has been made to the UK Listing Authority and to the London Stock
Exchange for 940,690,200 new dollar ordinary shares, being the issued share
capital of the company at the close of business on Friday 20 January 2006, to be
admitted to the Official List and, following approval and admission, trading in
the new dollar shares commences today. The company's shares continue to be
quoted in sterling on the London Stock Exchange.
In addition, application has been made to the UK Listing Authority and to the
London Stock Exchange, and approval given, for 7,462,500 ordinary shares to be
blocklisted for admission to the Official List under the following schemes. The
shares, which will rank pari passu in all respects with the new dollar shares in
issue, will be not be allotted immediately but as and when required pursuant to
the rules of the company's share option plans.
1991 Overseas Employee Share Option Scheme - 27,500
International Employees Share Option Scheme - 1,000,000
1985 Executive Share Option Scheme - 85,000
1990 International Executive Share Option Scheme - 1,850,000
2001 US Share Option Scheme - 1,500,000
2001 UK Approved Share Option Scheme - 500,000
2001 UK Unapproved Share Option Scheme - 1,000,000
UK Employee Share Option Scheme - 1,500,000.
Enquiries
Paul Chambers Tel: +44 (0) 20 7401 7646
Smith & Nephew
Company Secretary
Liz Hewitt Tel: +44 (0) 20 7401 7646
Smith & Nephew
Group Director Corporate Affairs
About us
Smith & Nephew is a global medical technology business, specialising in
Orthopaedics, Endoscopy and Advanced Wound Management products. Smith & Nephew
is a global leader in arthroscopy and advanced wound management and is one of
the fastest growing global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The company
prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The company has over 8,500
employees and operates in 33 countries around the world generating annual sales
of US$2.26 billion.